Concepedia

Pier Francesco Ferrucci

PF

Statistics

Publications

94

Citations

26.7K

H-Index

48

Active since

1993

Affiliations

European Institute of Oncology(Current)

Istituti di Ricovero e Cura a Carattere Scientifico

Istituto Oncologico Veneto

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

The Maria Sklodowska-Curie National Research Institute of Oncology

Pier Francesco Ferrucci is an author at European Institute of Oncology specializing in oncology, immunotherapy, and cancer immunotherapy.

ORCID

Publications per year

1993–2025

94

Publications

94

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text

, , +17

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text

, , +17

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2019 · 3.7K citations · Full text

, , +14

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

F. Stephen Hodi, Vanna Chiarion‐Sileni, René González et al. · The Lancet Oncology · 2018 · 1.4K citations

, , +16

The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells

F Grignani, Pier Francesco Ferrucci, Ugo Testa et al. · Cell · 1993 · 610 citations

, , +11

1–5 of 94